The first triple agonist (GLP-1 + GIP + Glucagon) just posted the highest weight loss ever recorded in clinical trials. Here's the full breakdown.
Every GLP-1 drug on the market right now targets one or two hormones. Semaglutide (Wegovy/Ozempic) targets GLP-1 alone. Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP — two hormones. Both have been game-changers.
Retatrutide targets three.
In December 2025, Eli Lilly announced that retatrutide — the first triple hormone receptor agonist ever tested in obesity — produced 28.7% average body weight loss in its first Phase 3 trial. That's the highest weight loss ever recorded for any medication in a clinical trial. And for men carrying 100+ excess pounds, it represents something genuinely new: the possibility of approaching surgical-level weight loss with a weekly injection.
Retatrutide activates receptors for three hormones simultaneously:
GLP-1 (glucagon-like peptide-1): Reduces appetite, slows gastric emptying, improves insulin sensitivity. This is what Wegovy does.
GIP (glucose-dependent insulinotropic polypeptide): Enhances insulin release, may improve fat metabolism and reduce inflammation. This is what Mounjaro adds on top of GLP-1.
Glucagon: This is the new piece. Glucagon increases energy expenditure and promotes direct fat burning in the liver. It's the reason retatrutide achieves weight loss numbers that dual agonists can't match.
Think of it this way: GLP-1 reduces what goes in. GIP improves how your body processes what's already there. Glucagon increases what gets burned. Together, they create a metabolic environment where the body is simultaneously eating less, storing less, and burning more.
TRIUMPH-4 enrolled approximately 450 adults with obesity or overweight who also had knee osteoarthritis. Participants were randomized to retatrutide 9 mg, 12 mg, or placebo for 68 weeks.
| Outcome | Retatrutide 12 mg | Placebo |
|---|---|---|
| Average weight loss | 28.7% (~71 lbs) | Minimal |
| Knee pain reduction (WOMAC) | 75.8% improvement | Modest |
| Patients pain-free at end | >12.5% (1 in 8) | Rare |
| Non-HDL cholesterol | Significant reduction | No change |
| Systolic blood pressure | Significant reduction | No change |
To translate those numbers: a 280-pound man on retatrutide could expect to lose approximately 80 pounds over 16 months. That puts retatrutide in the territory of gastric sleeve surgery — but without the operating room.
| Drug | Targets | Avg Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15-17% | FDA-approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~20-22% | FDA-approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~28.7% | Phase 3 trials (not approved) |
TRIUMPH-4 is the first of eight Phase 3 trials in the TRIUMPH program. Seven more are expected to report throughout 2026, testing retatrutide in:
Key unanswered questions:
Long-term safety: The glucagon receptor activation raises theoretical concerns about blood sugar stability and potential long-term cardiovascular effects. The TRIUMPH program is designed to answer these questions, but we don't have the data yet.
Muscle loss: With 28.7% weight loss, the absolute amount of lean mass lost could be significant. None of the TRIUMPH trial results released so far have specifically reported body composition data (DXA scans).
Side effects at higher weight loss: GI side effects (nausea, diarrhea, vomiting) were reported as generally mild and infrequent in TRIUMPH-4. But a unique side effect — dysesthesia (tingling or burning sensations) — has been observed in some participants and needs monitoring in larger trials.
Here's the realistic timeline:
Prediction markets currently give about a 27% chance of FDA approval in 2026 — reflecting the mathematical near-impossibility of getting through the full review process by December. The smart money says 2027-2028 for approval, with prescription availability following shortly after.
Retatrutide isn't available yet. But FDA-approved GLP-1 options delivering 15-22% weight loss are available today.
Compare Providers →Let's be direct: compounded retatrutide is not legal for human use in the United States. Retatrutide is an investigational drug that has not been approved by the FDA. It cannot legally be prescribed, compounded, or sold for therapeutic use outside of clinical trials.
Some grey-market peptide vendors sell "research-grade" retatrutide, but these products have no quality guarantees, no dosing guidance, and no medical oversight. The FDA has explicitly warned against using unapproved peptides — including retatrutide — in compounded products.
If you see a telehealth company offering compounded retatrutide, run. It's illegal, unsafe, and a sign that the provider isn't operating within legal bounds.
Retatrutide represents the next frontier in obesity pharmacotherapy. A 28.7% average weight loss with a once-weekly injection would be the most effective non-surgical weight loss intervention ever approved — if it makes it through the remaining trials and FDA review.
For men, the implications are enormous. The combination of massive weight loss, joint pain relief, cardiovascular marker improvements, and the potential for testosterone normalization (given the ENDO 2025 data on GLP-1s and hormones) makes retatrutide a potential all-in-one metabolic reset.
But it's not here yet. The best move right now is to start with the tools that are available — semaglutide or tirzepatide — and position yourself for retatrutide when it arrives. The men who started GLP-1 therapy in 2024 are already 50-80 pounds lighter by now. Don't wait for perfect when good is already here.